Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Recce Pharmaceuticals Ltd. ( (AU:RCE) ) has provided an update.
Recce Pharmaceuticals Ltd. announced the granting of a patent in Hong Kong for its anti-infective products, RECCE® 327 and RECCE® 529, which are used to treat various infections. This patent strengthens Recce’s intellectual property portfolio in Asia, supporting its strategy to enter markets with significant medical and commercial potential, such as the ASEAN region, where it is also progressing with a Phase 3 clinical trial in Indonesia.
The most recent analyst rating on (AU:RCE) stock is a Hold with a A$0.50 price target. To see the full list of analyst forecasts on Recce Pharmaceuticals Ltd. stock, see the AU:RCE Stock Forecast page.
More about Recce Pharmaceuticals Ltd.
Recce Pharmaceuticals Ltd. is a leading developer in the pharmaceutical industry, specializing in a new class of synthetic anti-infectives. The company focuses on creating treatments for bacterial and viral infections, with a market focus on regions with growing demand for advanced anti-infective solutions.
Average Trading Volume: 121,255
Technical Sentiment Signal: Hold
Current Market Cap: A$121.5M
See more data about RCE stock on TipRanks’ Stock Analysis page.